Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study Article

Wesolowski, Robert, Stover, Daniel G, Lustberg, Maryam B et al. (2020). Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study . 25(8), E1158-E1169. 10.1634/theoncologist.2020-0039

Open Access

cited authors

  • Wesolowski, Robert; Stover, Daniel G; Lustberg, Maryam B; Shoben, Abigail; Zhao, Meng; Mrozek, Ewa; Layman, Rachel M; Macrae, Erin; Duan, Wenrui; Zhang, Jun; Hall, Nathan; Wright, Chadwick L; Gillespie, Susan; Berger, Michael; Chalmers, Jeffrey J; Carey, Alahdra; Balasubramanian, Priya; Miller, Brandon L; Amaya, Peter; Andreopoulou, Eleni; Sparano, Joseph; Shapiro, Charles L; Villalona-Calero, Miguel Angel; Geyer, Susan; Chen, Alice; Grever, Michael R; Knopp, Michael; Ramaswamy, Bhuvaneswari

sustainable development goals

authors

publication date

  • June 17, 2020

webpage

keywords

  • ABT-888
  • BRCA1
  • CYCLOPHOSPHAMIDE
  • DNA-DAMAGE RESPONSE
  • FANCONI-ANEMIA
  • Fluorothymidine positron emission tomography scan
  • Homologous recombination DNA repair
  • Life Sciences & Biomedicine
  • Metastatic breast cancer
  • NEOADJUVANT CHEMOTHERAPY
  • Oncology
  • PARP INHIBITOR VELIPARIB
  • Phase I clinical trials
  • Poly(ADP-ribose) polymerase inhibitors
  • REPAIR
  • SYNTHETIC LETHALITY
  • Science & Technology
  • TUMORS

Digital Object Identifier (DOI)

publisher

  • WILEY

start page

  • E1158

end page

  • E1169

volume

  • 25

issue

  • 8